文献速递白血病造血干细胞移植与细胞治疗

异基因干细胞移植在伴t(8;16)(p11;p13)易位的急性髓系白血病中的作用

The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13).
PubMed 文献 · Am J Hematol · 2024-11-18

欧洲血液与骨髓移植学会 registry 研究纳入60例伴t(8;16)(p11;p13)易位的急性髓系白血病移植受者,2年总生存/无白血病生存为43%/39%;首次完全缓解期移植者(n=44)为48%/48%。多因素分析显示复杂核型是复发(HR 4.17,p=.016)、较低无白血病生存(HR 3.38,p=.01)和较低总生存(HR 3.08,p=.017)的主要危险因素。

要点

  • 60例t(8;16)急性髓系白血病移植受者2年总生存/无白血病生存为43%/39%。
  • 首次完全缓解期移植者(n=44)2年总生存/无白血病生存均为48%。
  • 复杂核型者2年总生存/无白血病生存为19%/19%,非复杂核型者为67%/67%。

核心结论

  • 异基因干细胞移植可能减轻不伴复杂核型的t(8;16)急性髓系白血病患者的不良风险,尤其在首次完全缓解期进行移植时。

研究设计与样本

  • 欧洲血液与骨髓移植学会开展的一项注册研究,纳入60例伴t(8;16)(p11;p13)易位的急性髓系白血病移植受者。

主要发现

  • 全部60例移植受者2年总生存/无白血病生存为43%/39%。
  • 首次完全缓解期移植者(n=44)2年总生存/无白血病生存均为48%。
  • 首次完全缓解期移植后多因素分析显示,复杂核型是复发的危险因素(HR 4.17,p=.016)、较低无白血病生存的危险因素(HR 3.38,p=.01)和较低总生存的危险因素(HR 3.08,p=.017)。
  • 复杂核型患者2年总生存/无白血病生存为19%/19%,非复杂核型的t(8;16)患者为67%/67%。
  • 其他不良结局因素包括年龄较大和继发性急性髓系白血病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) represents a rare entity that has been categorized as a disease-defining recurring cytogenetic abnormality with adverse risk in the 2022 European LeukemiaNet classification. This rating was mainly based on a retrospective analysis comprising patients from several large clinical trials, which, however, included only 21 patients treated with allogeneic stem cell transplantation (alloSCT). Therefore, the European Society for Blood and Marrow Transplantation performed a registry study on a larger cohort to evaluate the role of alloSCT in t(8;16) AML. Sixty transplant recipients with t(8;16) AML were identified. Two-year overall and leukemia-free survival (OS/LFS) was 43/39%. Patients transplanted in first complete remission (CR1, n = 44) achieved a 2-year OS/LFS of 48%/48%. Following alloSCT in CR1, the multivariable analysis identified a complex karyotype (CK) as a major risk factor for relapse (HR 4.17, p = .016), lower LFS (HR 3.38, p = .01), and lower OS (HR 3.08, p = .017). Two-year OS/LFS of patients with CK was 19%/19%, in contrast to 67%/67% in patients with t(8;16) outside a CK. Other factors for inferior outcomes were older age and secondary AML. In summary, alloSCT could mitigate the adverse risk of patients with t(8;16) AML not harboring a CK, particularly when performed in CR1.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Schmälter AK, Labopin M, Versluis J, et al. The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13). Am J Hematol. 2024. PMID: 39558209. doi:10.1002/ajh.27496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。